US5882327A - Long-term glaucoma drainage implant - Google Patents

Long-term glaucoma drainage implant Download PDF

Info

Publication number
US5882327A
US5882327A US08/839,263 US83926397A US5882327A US 5882327 A US5882327 A US 5882327A US 83926397 A US83926397 A US 83926397A US 5882327 A US5882327 A US 5882327A
Authority
US
United States
Prior art keywords
drainage
plate
conduit
porous
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/839,263
Inventor
Jean T. Jacob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University and Agricultural and Mechanical College
Original Assignee
Jacob; Jean T.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacob; Jean T. filed Critical Jacob; Jean T.
Priority to US08/839,263 priority Critical patent/US5882327A/en
Application granted granted Critical
Publication of US5882327A publication Critical patent/US5882327A/en
Assigned to BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE reassignment BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JACOB, JEAN T.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00781Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment

Definitions

  • the present invention relates to a glaucoma drainage implant which allows fluid to filter out from the eye.
  • a glaucoma drainage implant which allows fluid to filter out from the eye.
  • One in 30 Americans over the age of 40 has some form of glaucoma. All types of glaucoma are characterized by an excessive accumulation of aqueous humor in the anterior chamber of the eye, which results in increased intraocular pressure, visual field loss, optic disc cupping, and when left untreated, blindness. To date, there is no known cure for any type of glaucoma.
  • Wound healing is a postinflammatory process that represents the effort of the body to repair and to restore the integrity and function of damaged tissue.
  • the wound healing in response to filtration surgery is complicated by the presence of an activating factor (the aqueous humor) and, in the case of drainage implants, the presence of the implant itself.
  • Encapsulation by a fibrous capsule is the normal wound healing response of the host to an implant and to the associated local trauma caused by the implantation process.
  • the extent of the development of the fibrous capsule adjacent to a prosthetic implant is related to both the size and surface characteristics of the implant as well as to the degree of chemical inertness.
  • Failed long-term drainage implants in human eyes have been shown to have dense fibrous capsules that ultimately cut off flow from the plate region.
  • One reason for development of such a thick capsule around the implants is the chronic micromovement of the implant against the scleral surface, as discussed above.
  • the device By designing a drainage device with porous cellular-attachment surfaces on the posterior plate surface and around the exterior surface of the tube, the device will be able to fix in place at the bleb site during the early healing period so that it will be sufficiently immobile as to offer little to no stimulus for further fibroblast activation.
  • U.S. Pat. No. 5,338,291 to Speckman et al. uses texturing of the silicone surfaces of the drainage device plate to interrupt the formation of a dense fibrous capsule around the episcleral plate and to promote vascularization around said plate.
  • the textured surface of Speckman's plate comprises a plurality of fingers extending generally uniformly and outwardly from the episcleral plate. The textured surfaces are used to cause an interruption of the fibrous capsule formation resulting in multi-planar collagen deposition.
  • holes which extend through the plate to facilitate the formation of a tethered scar tissue bubble/bleb. It is intended that the scar tissue will grow through the hole or holes and pull the perimeter of the bubble/bleb towards the episcleral plate at the hole locations to tether the formation of the bleb through the plate to the scleral tissue.
  • the texturing system disclosed by Speckman has certain disadvantages.
  • the cells and collagen of the fibrous capsule wrap around the perpendicular length of the projections but do not attach to them. Therefore the fibrous capsule response around the finger-like texturing only helps to immobilize the implant from side to side motion in the plane parallel to the sclera.
  • There remains a small space between the texturing and the capsule which allows the implant to move perpendicular to the sclera in response to the dynamic movements of the eye, such as muscle movements to produce accommodation, and flexure of the sclera produced by blinking and intraocular pressure fluctuations.
  • the micromovement of the device is somewhat decreased but not eliminated with the texturing.
  • Speckman teaches that the anterior surface of their device is textured in addition to the posterior surface to interrupt dense fibrous capsule formation and to promote vascularization around the plate. However, this will allow the fibrous capsule to form around the texturing points on the anterior surface as well as on the posterior surface.
  • the area for the aqueous humor to flow over and spread (bleb space) is significantly decreased with the microtexturing and is almost completely eliminated when the fibrous capsule forms around the texturing.
  • the holes taught by Baerveldt have other types of disadvantages.
  • the holes require that the cells grow through the thickness of the plate, generally one millimeter, isolating themselves from other cells.
  • the circumferential size of the holes particularly in view of the thickness of the plate and the smooth surface of the hole walls, present a very difficult surface area for the cells to try and attach to while growing. The overall effect of these parameters limit cellular ingrowth through the holes.
  • the present invention provides an aqueous humor drainage device to relieve the elevated intraocular pressure associated with glaucoma.
  • the device consists of a flexible drainage conduit connected to a pliable episcleral drainage plate with porous cellular attachment areas around the proximal end of the conduit and the sides and posterior surface of the drainage plate.
  • the anterior aspect of the drainage plate is smooth and acts as a basin for the aqueous humor.
  • the device allows the natural healing response, i.e., the formation of a fibrous capsule, around the implant to improve the adhesion of the device to the sclera.
  • Cellular infiltration and collagen deposition into the porous aspects of the device forms a tight junction between the device and the sclera, preventing movement of the device.
  • the formation of the fibrous capsule includes cellular infiltration and collagen deposition into the porous areas on the conduit, which causes both the anterior and posterior tissues surrounding the drainage conduit to adhere to the circumference of the conduit.
  • tacking the anterior tissues to the conduit by fibrous capsule tissue ingrowth also helps to limit the bleb size. This is important since abnormally large blebs can cause ocular motor problems. Therefore the movement of device and the ultimate thickness of the fibrous capsule surrounding the device is kept to a minimum by the device provided for herein.
  • the porous surfaces of the device can have a average pore size ranging from 15 to 95 microns with the preferred surface having a nominal pore size of 35 microns.
  • the porous structure of the surfaces allows for cellular infiltration and collagen deposition through the pores and around the walls of the pores such that movement of the device is prevented not only from side to side but also perpendicularly to the scleral surface.
  • the porous surfaces can be of the same elastomeric material from which the drainage conduit and episcleral plate are made or can be made from another type of elastomeric material which is capable of being chemically or physically mated to both structures.
  • FIG. 1 is a partial sectional view of the eye showing the glaucoma drainage device of this invention implanted within the eye, extending from inside the anterior chamber to the external posterior portion of the globe, wherein an episcleral plate is surrounded by a fibrous capsule.
  • FIG. 2 is an enlarged bottom plane view of the glaucoma drainage device illustrated in FIG. 1.
  • FIG. 3 is an enlarged, fragmented sectional view of the glaucoma drainage device illustrated in FIG. 1, taken along line 3--3 in FIG. 5.
  • FIG. 4 is an enlarged partial view of the glaucoma drainage device illustrated in FIG. 3 showing the device implanted on the external posterior portion of the globe after the fibrous capsule has formed around it defining the bleb space.
  • FIG. 5 is an enlarged top view of the glaucoma drainage device illustrated in FIG. 1.
  • FIG. 6 is an enlarged cross-sectional view taken along line 6--6 in FIG. 4.
  • FIG. 7 is an alternative embodiment of the device illustrated in FIG. 4 which shows a plug located in the drainage conduit.
  • the present invention is an improved, long-term glaucoma drainage device, generally denoted by reference number 10, for surgical implantation in the eye 31 as depicted in FIGS. 1 and 4.
  • the improved glaucoma drainage device 10 as illustrated in FIGS. 2 and 3 includes a drainage conduit 13 which is preferably flexible and tubular in shape.
  • the distal end 40 of conduit 13 is free, as best shown in FIGS. 1, 2 and 5.
  • the proximal end 41 of conduit 13 is attached to a drainage plate 14, as best shown in FIG. 3.
  • drainage conduit 13 The inner and outer surfaces of drainage conduit 13 are preferably smooth, with the exception of a portion of the outer surface of conduit 13 adjacent to its proximal end 41 which has a porous ingrowth surface 12, as best shown in FIGS. 2 and 3.
  • Drainage plate 14 has a non-porous anterior surface 15 for aqueous fluid dispersement and a porous posterior surface 16 for cellular ingrowth and attachment to the scleral surface as shown in FIGS. 2, 3 and 4.
  • the drainage device 10 is implanted by a surgical procedure wherein the episcleral drainage plate 14 is attached to the external posterior surface of the sclera 20 of an eye 31, and the distal end 40 of conduit 13 is inserted into the anterior chamber 25 of the eye.
  • FIG. 1 illustrates the device 10 implanted within the eye 31.
  • the sclera 20 is the thick collagenous membrane which forms the outer walls of the almost ellipsoidal eye 31 except at the anterior central median where the thin optical membrane known as the cornea 26 forms a window into the eye.
  • the sclera 20 deforms and responds to extraocular muscle movements and ocular pressure changes that occur during normal physiological functions of the eye.
  • the junction where the cornea 26 and sclera 20 merge is referred to as the limbus 24.
  • the conjunctiva 22 is a membrane of tissue which extends posteriorly from the limbus 24 over the front portion of the sclera 20 and then projects in a forward direction lining the upper and lower eyelids 30.
  • Tenon's capsule 21 is a thin tissue membrane that attaches anteriorly at the limbus 24 beneath the conjunctiva 22 and extends posteriorly over the sclera 20 and extraocular muscles to attach at the back of the bony orbit within which the eye sits.
  • the ciliary body 28 begins internally in the eye at the limbus 24 and extends along the interior of the sclera 20.
  • the anterior chamber 25 of the eye which is bound anteriorly by the cornea 26 and posteriorly by the iris 29, is filled with a fluid produced primarily by the ciliary body 28, said fluid being referred to as the aqueous humor.
  • the aqueous humor passes through the Trabecular meshwork 27 into the canal of Schlemm 23, and from Schlemm's canal the aqueous humor is subsequently drained into the veins leaving the eye 31.
  • the intraocular pressure of the eye is produced by the amount of aqueous humor within the eye at any time and, in a normal and healthy eye, is maintained at a constant level by natural bodily functions which balance the production and outflow of the aqueous humor.
  • the disease state of glaucoma is most often characterized by an abnormally elevated intraocular pressure from either overproduction or decreased outflow of the aqueous humor.
  • the present invention 10 is designed as a surgical intervention for uncontrolled glaucoma by facilitating the outflow of aqueous humor from the eye.
  • the drainage device 10 When surgically implanted, as shown in FIGS. 1 and 4, the drainage device 10 allows aqueous humor from the anterior chamber 25 to drain out of the eye through the drainage conduit 13 to the drainage plate 14 where it is dispersed through the filtration bleb 36 and then the fibrous capsule 35 that forms around the plate 14.
  • the formation of fibrous capsule 35 around device 10 is a result of the natural wound-healing response to a foreign body or implant in the body that cannot be digested by macrophages, i.e., the implant is surrounded with a fibrous capsule to "wall" it if off from the rest of the body tissue. Fibrous capsule 35 formation first occurs in the range of 2 to 8 weeks post-implantation.
  • FIGS. 1 and 4 specifically depict the position of the device after it has been implanted for several months, showing how the fibrous capsule 35 forms around not only the posterior portion and edges of drainage plate 14 but also anterior to the plate along Tenon's capsule 21.
  • Drainage plate 14 which is preferably pliable, is implanted beneath Tenon's capsule 21 so that the porous posterior surface 16 of drainage plate 14 is placed flush with the sclera 20.
  • drainage plate 14 is provided with flange 19 and suture holes 17 so that the plate can be anchored with sutures to the sclera 20.
  • drainage conduit 13 extends forward underneath Tenon's capsule 21 and the distal end 40 of drainage conduit 13 is inserted into the anterior chamber 25 through the sclera 20 just posterior of the limbus 24 and cornea 26.
  • the porous ingrowth surface 12 of conduit 13 lays over the sclera 20 and the smooth portion of drainage conduit 13 extends into the anterior chamber 25 just anterior to the iris 29.
  • drainage plate 14 is preferably circular or elliptical in general shape with an overall curvature and flexibility that allows it to conform to the curvature of the eye such that it may be implanted flush against the curved surface of the sclera.
  • the plate 14 can be made from suitably pliable material such as elastomeric-type polymer materials like polysiloxane, polyurethane, polyethylene, polypropylene, polymethacrylate, polyacrylate and/or copolymers and/or derivatives thereof.
  • the anterior surface 15 of plate 14 is preferably smooth and non-porous and may be treated with chemical moieties or be made of a polymer imparting a surface energy or sufficient degree of hydrophilicity to facilitate spreading of the aqueous fluid which flows out of conduit 13 and onto the anterior surface 15 of the plate.
  • the porous ingrowth posterior surface 16 of plate 14 can be made of the same material as the plate or another suitably porous material such as expanded polytetrafluoroethylene.
  • the porous ingrowth surface 16 can be made as part of the plate in an injection molding process or can be fixed onto the plate with a suitable adhesive or bonding method.
  • the porous ingrowth surface 16 preferably wraps around the side 70 of drainage plate 14, as shown best in FIG. 3.
  • the porous ingrowth surface 16 preferably has a depth "D" of 0.35 mm to 1.25 mm, as shown in FIG. 3.
  • the pores 50 of porous surface 16 can be irregular in shape, as shown in FIG. 4, having an average pore size in the range of 15 to 90 microns with the preferred surface having a nominal pore size of 35 microns.
  • the preferred silicone embodiment of the device includes a porous silicone material, such as Interpore IP 100 made by Interpore International, Irvine, Calif., affixed to the edges and posterior portion of a silicone elastomer drainage plate with a medical grade silicone adhesive like Griffinedic Adhesive (Rehau, Inc, Elk Grove Village, Ill.) to serve as porous surface 16.
  • a porous silicone material such as Interpore IP 100 made by Interpore International, Irvine, Calif., affixed to the edges and posterior portion of a silicone elastomer drainage plate with a medical grade silicone adhesive like Kunststoffedic Adhesive (Rehau, Inc, Elk Grove Village, Ill.) to serve as porous surface 16.
  • plate 14 is preferably provided with a raised ridge 18 rising above the anterior surface 15 in the general area where the drainage conduit 13 is attached to the plate.
  • a suitable opening is provided in raised ridge 18 to permit the proximal end 41 of conduit 13 to pass through ridge 18.
  • the proximal end 41 of conduit 13 is attached to plate 14 by solvent, adhesive, heat or other suitable bonding.
  • the purpose of the raised ridge 18 is to give stability to the bonding site and to prevent Tenon's and fibrous capsule tissue from clogging or blocking the lumen 60 of the drainage conduit 13.
  • Conduit 13 from its distal end 40 to its proximal end 41, is approximately 2-3 cms in length.
  • Conduit 13 has a preferred inside diameter in the range of 0.011 to 0.015 inches and an overall outside diameter in the range of 0.020 to 0.035 inches, except for the portion of conduit 13 which has the porous ingrowth surface 12.
  • the porous ingrowth surface 12 extends approximately 5-10 mms along the length of conduit 13.
  • Pores 51 in ingrowth surface 12 have the same size range and preference as the pores 50 of porous surface 16.
  • Porous ingrowth surface 12 can be made out of the same material as conduit 13 or another polymer suitable for cellular ingrowth. Porous ingrowth surface 12 can be made as part of conduit 13, as in an injection molding process, or it can be fixed onto the conduit with a suitable adhesive or bonding method. Porous ingrowth surface 12 preferably has a depth of 0.30 mm to 3 mm, i.e., ingrowth surface 12 protrudes about 0.30 to 3 mm beyond the smooth outer surface of conduit 13. Porous ingrowth surface 12 is located adjacent to the proximal end 41 of conduit 13. Due to mechanical considerations, such as the adhesive attachment of porous ingrowth surface 12 to conduit 13, there may be a small length of conduit 13, between ingrowth surface 12 and the proximal end 41 of conduit 13, which is smooth as shown in FIG. 4. Alternatively, porous ingrowth surface 12 may extend along conduit 13 to the point where its proximal end 41 passes through raised ridge 18 of plate 14.
  • conduit 13 may be treated with chemical moieties or be made of a polymer imparting a surface energy or sufficient degree of hydrophilicity to facilitate the flow of aqueous fluid through the conduit.
  • a preferred embodiment of conduit 13 is a silastic tubing such as silicone tube N5941 distributed by Storz Instrument Co, St. Louis, Mo. with Interpore IP100 (Interpore, Irvine, Calif.) wrapped and glued with medical grade silicone adhesive (Rehau, Inc, Elk Grove Village, Ill.) around the outer surface of the conduit to serve as ingrowth surface 12.
  • the shape and configuration of the pores 50 in porous surface 16 of plate 14 is similar to the shape and configuration of the pores 51 in ingrowth surface 12.
  • the pores extend from the surface into the interior of the material.
  • the pores can be continuous with each other and form a network in the material into which cells can migrate and deposit collagen within.
  • the pores can be created by blowing gas through the polymer during manufacture, polymerizing a foam in place, weaving polymer strands, spin extruding/casting polymer into a mesh, removing a soluble mold or salt from the cast polymer or other suitable methods.
  • FIG. 4 gives a general representation of how porous ingrowth surface 12 and porous surface 16 have discrete openings, i.e., pores, and that the polymer forms the walls of said pores.
  • pores 50a and 51a as shown in FIG. 4 Some of the pores may be partly encapsulated or enveloped by the polymer, as for example pores 50a and 51a as shown in FIG. 4, thereby creating porous "tunnels.”
  • Such porous tunnels in the case of porous surface 16, do not extend all the way through plate 14 but instead loop back around such that the entrances and exits of said tunnels are located on the posterior surface of plate 14.
  • fibrous capsule 35 includes cellular infiltration and collagen deposition into pores 50 and 51, which facilitates and promotes adherence of the device 10 to the sclera 20.
  • cellular ingrowth of the fibrous capsule into pores 50 and 51 securely anchors the implant in place and, unlike prior drainage implants, prevents any independent movement of the implant in any direction, whether parallel or perpendicular to the surface of the sclera.
  • the implant responds to normal ocular physiological functions as part of the sclera and is not recognized by the body as an object independent of the sclera. Accordingly, ingrowth surface 12 and porous surface 16 have the effect of significantly decreasing, if not totally eliminating, micromovement of drainage device 10 relative to the sclera.
  • any micromovement of the implant can continue to activate the foreign-body response of the eye and increase the fibrous capsule thickness around the implant.
  • Such increased fibrous capsule thickness is detrimental because it may cut off or significantly restrict the flow of aqueous humor from the plate.
  • Bleb function is dependent upon the dissipation of the aqueous fluid through the walls of the bleb 36 which are formed by the fibrous capsule 35.
  • drainage of aqueous humor from the eye 31 through the device 10 is unrestricted and can result in dangerously low intraocular pressure or hypotony of the eye.
  • sutures can be tied tightly around the drainage conduit as it lays over the sclera to close the lumen 60 of the conduit.
  • a suture can be threaded through lumen 60 of the drainage conduit during implantation so that it plugs any flow through the conduit, with the free end of the suture passed inferiorly under the conjunctiva 22 and out at the inferonasal limbus and then sutured to the globe with interrupted sutures.
  • the sutures are removed several weeks after implantation.
  • a third method forpreventing early postoperative hypotony after implantation is by fitting a biodegradable plug into the lumen 60 of the drainage conduit 13 adjacent to its proximal end 41. The biodegradable plug will dissolve slowly over time, losing its continuity or mass, eventually allowing aqueous humor to flow out of the conduit and onto the plate.
  • drainage conduit 13 may be provided with a drainage plug 61, as shown in FIG. 7, which contains drugs designed to prevent excessive fibrous capsule formation.
  • Plug 61 is placed in the lumen 60 of the drainage conduit 13 as a drug delivery system. Drug is delivered to the tissues surrounding the bleb 36 slowly as the plug degrades and fluid flows from the anterior chamber.
  • the plug 61 is made to fit snugly within the lumen 60 and is placed in the proximal end 41 of the conduit.
  • the plug is hydrophilic in nature and swells within the conduit by imbibing the aqueous fluid that enters the conduit from the anterior chamber.
  • the slight swelling of the plug 61 within the lumen 60 helps the plug 61 resist any intraocular pressure and maintain its position within the lumen 60 prior to dissolution/degradation.
  • the drug within the plug 61 is concentrated in the center and proximal-most end of the plug to prevent possible flow of drug into the anterior chamber.
  • the drugs within the plug may include antiproliferative drugs, as for example 5-fluorouracil (5-FU), mitomycin C, bleomycin, taxol, daunorubicin and anthracyclines; drugs which affect collagen crosslinking, as for example beta-aminopropionitrile; drugs to increase fibrinolytic activity, as for example tissue plasminogen activator, and other suitable drugs.
  • antiproliferative drugs as for example 5-fluorouracil (5-FU), mitomycin C, bleomycin, taxol, daunorubicin and anthracyclines
  • drugs which affect collagen crosslinking as for example beta-aminopropionitrile
  • drugs to increase fibrinolytic activity as for example tissue plasminogen activator, and other suitable drugs.
  • Such drugs can be entrapped in or hydrolyzably linked to the polymer chains of the biodegradable plug 61, which is preferably formed from a biodegradable or hydrolyzable polymer such as collagen, hyaluronic acid, chitin, chitosan, polylactic acids, polyglycolic acids, polyacrylates, polymethacrylates, polyacrylic acids, polyethylene glycols and/or suitable copolymers and/or derivatives thereof.
  • a biodegradable or hydrolyzable polymer such as collagen, hyaluronic acid, chitin, chitosan, polylactic acids, polyglycolic acids, polyacrylates, polymethacrylates, polyacrylic acids, polyethylene glycols and/or suitable copolymers and/or derivatives thereof.
  • the device 10 is implanted in the eye 31 using standard ophthalmic procedures as described here briefly.
  • the conjunctiva 22 and Tenon's capsule 21 are radially incised proximal to the limbus 24.
  • the sclera bed 20 is exposed by blunt dissection of Tenon's capsule 21.
  • the drainage plate 14 of the device is then sutured to the sclera 20 approximately 8 mm from the limbus 24.
  • the anterior chamber 25 is entered with a small gauge needle, approximately 3 mm posterior to the limbus 24.
  • the drainage conduit 13 is measured and cut so that its distal end 40 reaches the iridopupillary border when it is passed through the needle track and inserted into the anterior chamber 25.
  • the conjunctiva 22--Tenon's 21 flap is re-approximated over plate 14 and conduit 13 and is sutured closed.
  • the anterior chamber 25 is reformed with an air bubble injected at the limbus 24.

Abstract

An implantable ocular device to decrease intraocular pressure by draining aqueous humor from the anterior chamber of the eye into an extraocular space above the sclera and below the conjunctiva and Tenon's layers. The device includes a conduit attached to an episcleral drainage plate having a porous posterior surface for cellular ingrowth and attachment by the sclera. The distal end of the conduit is inserted into the anterior chamber and protrudes out of the limbal/scleral junction. A portion of the outer surface of the conduit adjacent to the plate has a porous ingrowth surface area to enhance anchoring of the conduit to the surrounding extraocular tissues. The plate has a smooth anterior surface and a porous posterior surface. This device uses porous surfaces to enhance cellular infiltration and ingrowth to increase apposition with surrounding tissues, decrease micromovement of the implant, and thereby decrease the fibrous capsule formation surrounding the episcleral plate. Long-term failure of glaucoma drainage devices has been linked to thickening of the filtering bleb due to excessive fibrous capsule formation.

Description

FIELD AND BACKGROUND OF INVENTION
The present invention relates to a glaucoma drainage implant which allows fluid to filter out from the eye. One in 30 Americans over the age of 40 has some form of glaucoma. All types of glaucoma are characterized by an excessive accumulation of aqueous humor in the anterior chamber of the eye, which results in increased intraocular pressure, visual field loss, optic disc cupping, and when left untreated, blindness. To date, there is no known cure for any type of glaucoma.
Initially, medical therapy, i.e., topical medicine, is used to increase outflow and/or decrease production of aqueous humor. However, approximately, 40-50% of patients with glaucoma eventually fail medical therapy, and become candidates for complex forms of filtration surgery. These procedures, including full-thickness sclerectomy, trabeculectomy, and drainage implants, involve the making of a channel from the anterior chamber to the subTenon's space. The aqueous pool that accumulates under Tenon's layer forms a bleb from which the fluid is absorbed by the surrounding tissues.
One of the main reasons for the 10-50% failure rate of filtration surgery is inadequate reduction of intraocular pressure due to bleb failure (shunt closure) over either the short-term (weeks to months) or long-term (years) postoperative course. After the immediate postoperative period, the inability to maintain reduced intraocular pressure is the single most common serious complication of the three principal forms of filtration surgery mentioned above. Eyes with failed filtration surgery usually have no observable filtration bleb or have a thick-walled encapsulated bleb that is nearly impermeable. The bleb fails due to excessive healing characterized by fibroblastic proliferation and subconjunctival fibrosis. In eyes with inflammation, neovascularization, or previous intraocular surgery, this process of scarring is especially excessive.
Wound healing is a postinflammatory process that represents the effort of the body to repair and to restore the integrity and function of damaged tissue. The wound healing in response to filtration surgery is complicated by the presence of an activating factor (the aqueous humor) and, in the case of drainage implants, the presence of the implant itself. Encapsulation by a fibrous capsule is the normal wound healing response of the host to an implant and to the associated local trauma caused by the implantation process. The extent of the development of the fibrous capsule adjacent to a prosthetic implant is related to both the size and surface characteristics of the implant as well as to the degree of chemical inertness.
For implants in dynamic situations, such as vascular grafts, tendons, and patches on moving organs (heart, stomach, striated muscles, intestines), being smooth and inert is a hindrance to long term anchoring. Integration between the implant and the host is necessary to prevent detachment or shifting of the implant. Sutures are often inadequate for this purpose because simple tacking sutures allow the implant to shift and bulge. Suturing the entire length and circumference of the implant introduces the possibility of leakage of the internal organ fluid such as blood and bile through the suture holes and impairment of the strength of the implant. On the outside of the eye, porosity of the implant that allows integration of the host tissue would be very important in stabilizing the micromovement of an implant in such a dynamic environment. Infiltration of tissue into the implant from the sclera would increase the apposition between the bottom surface of the implant and the upper surface of the sclera to an extent that neither sutures nor a fibrous capsule would be able to approximate.
Failed long-term drainage implants in human eyes have been shown to have dense fibrous capsules that ultimately cut off flow from the plate region. One reason for development of such a thick capsule around the implants is the chronic micromovement of the implant against the scleral surface, as discussed above. By designing a drainage device with porous cellular-attachment surfaces on the posterior plate surface and around the exterior surface of the tube, the device will be able to fix in place at the bleb site during the early healing period so that it will be sufficiently immobile as to offer little to no stimulus for further fibroblast activation.
The use of cellular attachment around or through the drainage device is a known means of improving the apposition between the device and the surrounding tissues. U.S. Pat. No. 5,338,291 to Speckman et al. uses texturing of the silicone surfaces of the drainage device plate to interrupt the formation of a dense fibrous capsule around the episcleral plate and to promote vascularization around said plate. The textured surface of Speckman's plate comprises a plurality of fingers extending generally uniformly and outwardly from the episcleral plate. The textured surfaces are used to cause an interruption of the fibrous capsule formation resulting in multi-planar collagen deposition. Additionally, U.S. Pat. No. 5,397,300 to Baerveldt et al. uses holes which extend through the plate to facilitate the formation of a tethered scar tissue bubble/bleb. It is intended that the scar tissue will grow through the hole or holes and pull the perimeter of the bubble/bleb towards the episcleral plate at the hole locations to tether the formation of the bleb through the plate to the scleral tissue.
However, the texturing system disclosed by Speckman has certain disadvantages. The cells and collagen of the fibrous capsule wrap around the perpendicular length of the projections but do not attach to them. Therefore the fibrous capsule response around the finger-like texturing only helps to immobilize the implant from side to side motion in the plane parallel to the sclera. There remains a small space between the texturing and the capsule which allows the implant to move perpendicular to the sclera in response to the dynamic movements of the eye, such as muscle movements to produce accommodation, and flexure of the sclera produced by blinking and intraocular pressure fluctuations. Thus the micromovement of the device is somewhat decreased but not eliminated with the texturing.
Also, Speckman teaches that the anterior surface of their device is textured in addition to the posterior surface to interrupt dense fibrous capsule formation and to promote vascularization around the plate. However, this will allow the fibrous capsule to form around the texturing points on the anterior surface as well as on the posterior surface. The area for the aqueous humor to flow over and spread (bleb space) is significantly decreased with the microtexturing and is almost completely eliminated when the fibrous capsule forms around the texturing.
The holes taught by Baerveldt have other types of disadvantages. The holes require that the cells grow through the thickness of the plate, generally one millimeter, isolating themselves from other cells. The circumferential size of the holes, particularly in view of the thickness of the plate and the smooth surface of the hole walls, present a very difficult surface area for the cells to try and attach to while growing. The overall effect of these parameters limit cellular ingrowth through the holes. Additionally, if sufficient holes are placed throughout the episcleral plate to facilitate the cellular ingrowth through them, then there would no longer be sufficient surface area on the anterior surface of the plate to disburse the aqueous humor flowing thereon, and the tethers of cellular tissue through the plate would act as physical barriers impeding the dispersion of the aqueous humor.
SUMMARY OF INVENTION
The present invention provides an aqueous humor drainage device to relieve the elevated intraocular pressure associated with glaucoma. The device consists of a flexible drainage conduit connected to a pliable episcleral drainage plate with porous cellular attachment areas around the proximal end of the conduit and the sides and posterior surface of the drainage plate. The anterior aspect of the drainage plate is smooth and acts as a basin for the aqueous humor. The device allows the natural healing response, i.e., the formation of a fibrous capsule, around the implant to improve the adhesion of the device to the sclera. Cellular infiltration and collagen deposition into the porous aspects of the device forms a tight junction between the device and the sclera, preventing movement of the device. The formation of the fibrous capsule includes cellular infiltration and collagen deposition into the porous areas on the conduit, which causes both the anterior and posterior tissues surrounding the drainage conduit to adhere to the circumference of the conduit. In addition to increasing the degree of immobilization, tacking the anterior tissues to the conduit by fibrous capsule tissue ingrowth also helps to limit the bleb size. This is important since abnormally large blebs can cause ocular motor problems. Therefore the movement of device and the ultimate thickness of the fibrous capsule surrounding the device is kept to a minimum by the device provided for herein.
The porous surfaces of the device can have a average pore size ranging from 15 to 95 microns with the preferred surface having a nominal pore size of 35 microns. The porous structure of the surfaces allows for cellular infiltration and collagen deposition through the pores and around the walls of the pores such that movement of the device is prevented not only from side to side but also perpendicularly to the scleral surface. The porous surfaces can be of the same elastomeric material from which the drainage conduit and episcleral plate are made or can be made from another type of elastomeric material which is capable of being chemically or physically mated to both structures.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a partial sectional view of the eye showing the glaucoma drainage device of this invention implanted within the eye, extending from inside the anterior chamber to the external posterior portion of the globe, wherein an episcleral plate is surrounded by a fibrous capsule.
FIG. 2 is an enlarged bottom plane view of the glaucoma drainage device illustrated in FIG. 1.
FIG. 3 is an enlarged, fragmented sectional view of the glaucoma drainage device illustrated in FIG. 1, taken along line 3--3 in FIG. 5.
FIG. 4 is an enlarged partial view of the glaucoma drainage device illustrated in FIG. 3 showing the device implanted on the external posterior portion of the globe after the fibrous capsule has formed around it defining the bleb space.
FIG. 5 is an enlarged top view of the glaucoma drainage device illustrated in FIG. 1.
FIG. 6 is an enlarged cross-sectional view taken along line 6--6 in FIG. 4.
FIG. 7 is an alternative embodiment of the device illustrated in FIG. 4 which shows a plug located in the drainage conduit.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
As shown in the drawings for the purpose of illustration, the present invention is an improved, long-term glaucoma drainage device, generally denoted by reference number 10, for surgical implantation in the eye 31 as depicted in FIGS. 1 and 4. The improved glaucoma drainage device 10 as illustrated in FIGS. 2 and 3 includes a drainage conduit 13 which is preferably flexible and tubular in shape. The distal end 40 of conduit 13 is free, as best shown in FIGS. 1, 2 and 5. The proximal end 41 of conduit 13 is attached to a drainage plate 14, as best shown in FIG. 3. The inner and outer surfaces of drainage conduit 13 are preferably smooth, with the exception of a portion of the outer surface of conduit 13 adjacent to its proximal end 41 which has a porous ingrowth surface 12, as best shown in FIGS. 2 and 3. Drainage plate 14 has a non-porous anterior surface 15 for aqueous fluid dispersement and a porous posterior surface 16 for cellular ingrowth and attachment to the scleral surface as shown in FIGS. 2, 3 and 4.
The drainage device 10 is implanted by a surgical procedure wherein the episcleral drainage plate 14 is attached to the external posterior surface of the sclera 20 of an eye 31, and the distal end 40 of conduit 13 is inserted into the anterior chamber 25 of the eye. FIG. 1 illustrates the device 10 implanted within the eye 31.
The relevant structures of the eye and some of their functions will be briefly described to provide an understanding of the present invention. The sclera 20 is the thick collagenous membrane which forms the outer walls of the almost ellipsoidal eye 31 except at the anterior central median where the thin optical membrane known as the cornea 26 forms a window into the eye. The sclera 20 deforms and responds to extraocular muscle movements and ocular pressure changes that occur during normal physiological functions of the eye. The junction where the cornea 26 and sclera 20 merge is referred to as the limbus 24. The conjunctiva 22 is a membrane of tissue which extends posteriorly from the limbus 24 over the front portion of the sclera 20 and then projects in a forward direction lining the upper and lower eyelids 30. Tenon's capsule 21 is a thin tissue membrane that attaches anteriorly at the limbus 24 beneath the conjunctiva 22 and extends posteriorly over the sclera 20 and extraocular muscles to attach at the back of the bony orbit within which the eye sits.
The ciliary body 28 begins internally in the eye at the limbus 24 and extends along the interior of the sclera 20. The iris 29, which extends radially into the center void of the eye from the anterior section of the ciliary body 28, forms the edges of the central space known as the pupil 32 and acts as a diaphragm controlling the size of the pupil. The anterior chamber 25 of the eye, which is bound anteriorly by the cornea 26 and posteriorly by the iris 29, is filled with a fluid produced primarily by the ciliary body 28, said fluid being referred to as the aqueous humor. The aqueous humor passes through the Trabecular meshwork 27 into the canal of Schlemm 23, and from Schlemm's canal the aqueous humor is subsequently drained into the veins leaving the eye 31.
The intraocular pressure of the eye is produced by the amount of aqueous humor within the eye at any time and, in a normal and healthy eye, is maintained at a constant level by natural bodily functions which balance the production and outflow of the aqueous humor. The disease state of glaucoma is most often characterized by an abnormally elevated intraocular pressure from either overproduction or decreased outflow of the aqueous humor. The present invention 10 is designed as a surgical intervention for uncontrolled glaucoma by facilitating the outflow of aqueous humor from the eye.
When surgically implanted, as shown in FIGS. 1 and 4, the drainage device 10 allows aqueous humor from the anterior chamber 25 to drain out of the eye through the drainage conduit 13 to the drainage plate 14 where it is dispersed through the filtration bleb 36 and then the fibrous capsule 35 that forms around the plate 14. The formation of fibrous capsule 35 around device 10 is a result of the natural wound-healing response to a foreign body or implant in the body that cannot be digested by macrophages, i.e., the implant is surrounded with a fibrous capsule to "wall" it if off from the rest of the body tissue. Fibrous capsule 35 formation first occurs in the range of 2 to 8 weeks post-implantation. It is the formation of the fibrous capsule 35 around the drainage plate 14 that eventually defines the space of the filtration bleb 36. FIGS. 1 and 4 specifically depict the position of the device after it has been implanted for several months, showing how the fibrous capsule 35 forms around not only the posterior portion and edges of drainage plate 14 but also anterior to the plate along Tenon's capsule 21.
Drainage plate 14, which is preferably pliable, is implanted beneath Tenon's capsule 21 so that the porous posterior surface 16 of drainage plate 14 is placed flush with the sclera 20. To facilitate the surgical implantation, drainage plate 14 is provided with flange 19 and suture holes 17 so that the plate can be anchored with sutures to the sclera 20. As implanted, drainage conduit 13 extends forward underneath Tenon's capsule 21 and the distal end 40 of drainage conduit 13 is inserted into the anterior chamber 25 through the sclera 20 just posterior of the limbus 24 and cornea 26. The porous ingrowth surface 12 of conduit 13 lays over the sclera 20 and the smooth portion of drainage conduit 13 extends into the anterior chamber 25 just anterior to the iris 29.
As illustrated in FIGS. 2, 3 and 5, drainage plate 14 is preferably circular or elliptical in general shape with an overall curvature and flexibility that allows it to conform to the curvature of the eye such that it may be implanted flush against the curved surface of the sclera. The plate 14 can be made from suitably pliable material such as elastomeric-type polymer materials like polysiloxane, polyurethane, polyethylene, polypropylene, polymethacrylate, polyacrylate and/or copolymers and/or derivatives thereof. The anterior surface 15 of plate 14 is preferably smooth and non-porous and may be treated with chemical moieties or be made of a polymer imparting a surface energy or sufficient degree of hydrophilicity to facilitate spreading of the aqueous fluid which flows out of conduit 13 and onto the anterior surface 15 of the plate.
The porous ingrowth posterior surface 16 of plate 14 can be made of the same material as the plate or another suitably porous material such as expanded polytetrafluoroethylene. The porous ingrowth surface 16 can be made as part of the plate in an injection molding process or can be fixed onto the plate with a suitable adhesive or bonding method. The porous ingrowth surface 16 preferably wraps around the side 70 of drainage plate 14, as shown best in FIG. 3. The porous ingrowth surface 16 preferably has a depth "D" of 0.35 mm to 1.25 mm, as shown in FIG. 3. The pores 50 of porous surface 16 can be irregular in shape, as shown in FIG. 4, having an average pore size in the range of 15 to 90 microns with the preferred surface having a nominal pore size of 35 microns. The preferred silicone embodiment of the device includes a porous silicone material, such as Interpore IP 100 made by Interpore International, Irvine, Calif., affixed to the edges and posterior portion of a silicone elastomer drainage plate with a medical grade silicone adhesive like Raumedic Adhesive (Rehau, Inc, Elk Grove Village, Ill.) to serve as porous surface 16.
As shown in FIGS. 4 & 5, plate 14 is preferably provided with a raised ridge 18 rising above the anterior surface 15 in the general area where the drainage conduit 13 is attached to the plate. A suitable opening is provided in raised ridge 18 to permit the proximal end 41 of conduit 13 to pass through ridge 18. The proximal end 41 of conduit 13 is attached to plate 14 by solvent, adhesive, heat or other suitable bonding. The purpose of the raised ridge 18 is to give stability to the bonding site and to prevent Tenon's and fibrous capsule tissue from clogging or blocking the lumen 60 of the drainage conduit 13.
Conduit 13, from its distal end 40 to its proximal end 41, is approximately 2-3 cms in length. Conduit 13 has a preferred inside diameter in the range of 0.011 to 0.015 inches and an overall outside diameter in the range of 0.020 to 0.035 inches, except for the portion of conduit 13 which has the porous ingrowth surface 12. The porous ingrowth surface 12 extends approximately 5-10 mms along the length of conduit 13. Pores 51 in ingrowth surface 12 have the same size range and preference as the pores 50 of porous surface 16.
Porous ingrowth surface 12 can be made out of the same material as conduit 13 or another polymer suitable for cellular ingrowth. Porous ingrowth surface 12 can be made as part of conduit 13, as in an injection molding process, or it can be fixed onto the conduit with a suitable adhesive or bonding method. Porous ingrowth surface 12 preferably has a depth of 0.30 mm to 3 mm, i.e., ingrowth surface 12 protrudes about 0.30 to 3 mm beyond the smooth outer surface of conduit 13. Porous ingrowth surface 12 is located adjacent to the proximal end 41 of conduit 13. Due to mechanical considerations, such as the adhesive attachment of porous ingrowth surface 12 to conduit 13, there may be a small length of conduit 13, between ingrowth surface 12 and the proximal end 41 of conduit 13, which is smooth as shown in FIG. 4. Alternatively, porous ingrowth surface 12 may extend along conduit 13 to the point where its proximal end 41 passes through raised ridge 18 of plate 14.
The interior surface of conduit 13 may be treated with chemical moieties or be made of a polymer imparting a surface energy or sufficient degree of hydrophilicity to facilitate the flow of aqueous fluid through the conduit. A preferred embodiment of conduit 13 is a silastic tubing such as silicone tube N5941 distributed by Storz Instrument Co, St. Louis, Mo. with Interpore IP100 (Interpore, Irvine, Calif.) wrapped and glued with medical grade silicone adhesive (Rehau, Inc, Elk Grove Village, Ill.) around the outer surface of the conduit to serve as ingrowth surface 12.
The shape and configuration of the pores 50 in porous surface 16 of plate 14 is similar to the shape and configuration of the pores 51 in ingrowth surface 12. The pores extend from the surface into the interior of the material. The pores can be continuous with each other and form a network in the material into which cells can migrate and deposit collagen within. The pores can be created by blowing gas through the polymer during manufacture, polymerizing a foam in place, weaving polymer strands, spin extruding/casting polymer into a mesh, removing a soluble mold or salt from the cast polymer or other suitable methods. FIG. 4 gives a general representation of how porous ingrowth surface 12 and porous surface 16 have discrete openings, i.e., pores, and that the polymer forms the walls of said pores. Some of the pores may be partly encapsulated or enveloped by the polymer, as for example pores 50a and 51a as shown in FIG. 4, thereby creating porous "tunnels." Such porous tunnels, in the case of porous surface 16, do not extend all the way through plate 14 but instead loop back around such that the entrances and exits of said tunnels are located on the posterior surface of plate 14.
The formation of fibrous capsule 35 includes cellular infiltration and collagen deposition into pores 50 and 51, which facilitates and promotes adherence of the device 10 to the sclera 20. Hence, cellular ingrowth of the fibrous capsule into pores 50 and 51 securely anchors the implant in place and, unlike prior drainage implants, prevents any independent movement of the implant in any direction, whether parallel or perpendicular to the surface of the sclera. Hence, the implant responds to normal ocular physiological functions as part of the sclera and is not recognized by the body as an object independent of the sclera. Accordingly, ingrowth surface 12 and porous surface 16 have the effect of significantly decreasing, if not totally eliminating, micromovement of drainage device 10 relative to the sclera. This is important to the success of the implant because any micromovement of the implant can continue to activate the foreign-body response of the eye and increase the fibrous capsule thickness around the implant. Such increased fibrous capsule thickness is detrimental because it may cut off or significantly restrict the flow of aqueous humor from the plate.
Bleb function is dependent upon the dissipation of the aqueous fluid through the walls of the bleb 36 which are formed by the fibrous capsule 35. Prior to fibrous capsule formation, drainage of aqueous humor from the eye 31 through the device 10 is unrestricted and can result in dangerously low intraocular pressure or hypotony of the eye. There are several known ways to prevent such over-drainage of the eye prior to fibrous capsule formation. For example, sutures can be tied tightly around the drainage conduit as it lays over the sclera to close the lumen 60 of the conduit. As another example, a suture can be threaded through lumen 60 of the drainage conduit during implantation so that it plugs any flow through the conduit, with the free end of the suture passed inferiorly under the conjunctiva 22 and out at the inferonasal limbus and then sutured to the globe with interrupted sutures. For both of these methods, the sutures are removed several weeks after implantation. A third method forpreventing early postoperative hypotony after implantation is by fitting a biodegradable plug into the lumen 60 of the drainage conduit 13 adjacent to its proximal end 41. The biodegradable plug will dissolve slowly over time, losing its continuity or mass, eventually allowing aqueous humor to flow out of the conduit and onto the plate.
In an alternative embodiment of the present device 10, drainage conduit 13 may be provided with a drainage plug 61, as shown in FIG. 7, which contains drugs designed to prevent excessive fibrous capsule formation. Plug 61 is placed in the lumen 60 of the drainage conduit 13 as a drug delivery system. Drug is delivered to the tissues surrounding the bleb 36 slowly as the plug degrades and fluid flows from the anterior chamber. The plug 61 is made to fit snugly within the lumen 60 and is placed in the proximal end 41 of the conduit. In the preferred embodiment of the plug, the plug is hydrophilic in nature and swells within the conduit by imbibing the aqueous fluid that enters the conduit from the anterior chamber. The slight swelling of the plug 61 within the lumen 60 helps the plug 61 resist any intraocular pressure and maintain its position within the lumen 60 prior to dissolution/degradation. The drug within the plug 61 is concentrated in the center and proximal-most end of the plug to prevent possible flow of drug into the anterior chamber.
The drugs within the plug may include antiproliferative drugs, as for example 5-fluorouracil (5-FU), mitomycin C, bleomycin, taxol, daunorubicin and anthracyclines; drugs which affect collagen crosslinking, as for example beta-aminopropionitrile; drugs to increase fibrinolytic activity, as for example tissue plasminogen activator, and other suitable drugs. Such drugs can be entrapped in or hydrolyzably linked to the polymer chains of the biodegradable plug 61, which is preferably formed from a biodegradable or hydrolyzable polymer such as collagen, hyaluronic acid, chitin, chitosan, polylactic acids, polyglycolic acids, polyacrylates, polymethacrylates, polyacrylic acids, polyethylene glycols and/or suitable copolymers and/or derivatives thereof. As plug 61 dissolves, the drugs contained therein are released and delivered through conduit 13 onto plate 14 and ultimately to the tissues surrounding the bleb.
The device 10 is implanted in the eye 31 using standard ophthalmic procedures as described here briefly. The conjunctiva 22 and Tenon's capsule 21 are radially incised proximal to the limbus 24. The sclera bed 20 is exposed by blunt dissection of Tenon's capsule 21. The drainage plate 14 of the device is then sutured to the sclera 20 approximately 8 mm from the limbus 24. The anterior chamber 25 is entered with a small gauge needle, approximately 3 mm posterior to the limbus 24. The drainage conduit 13 is measured and cut so that its distal end 40 reaches the iridopupillary border when it is passed through the needle track and inserted into the anterior chamber 25. The conjunctiva 22--Tenon's 21 flap is re-approximated over plate 14 and conduit 13 and is sutured closed. The anterior chamber 25 is reformed with an air bubble injected at the limbus 24.

Claims (8)

What is claimed is:
1. A surgically implantable drainage device to facilitate the flow of aqueous humor from an eye comprising a drainage plate having an anterior surface defining a drainage basin and having a porous posterior surface, wherein said porous posterior surface includes pores having a pore size of about 15 to 90 microns to promote cellular ingrowth and attachment of the device to the sclera of the eye, and a drainage conduit having a proximal end which is attached to and is in fluid communication with the drainage plate and a distal end which is capable of being inserted into the anterior chamber of the eye such that aqueous humor may flow from the anterior chamber of the eye, through the drainage conduit, and onto the drainage plate.
2. The device of claim 1 wherein said drainage conduit has a porous ingrowth surface to facilitate and promote adherence of the device to the sclera.
3. A surgically implantable drainage device to facilitate the flow of aqueous humor from an eye, comprising
a drainage plate having a non-porous anterior surface defining a drainage basin and a posterior surface, wherein said posterior surface includes pores having a pore size of about 15 to 90 microns to promote cellular ingrowth and attachment of the device to the sclera of the eye; and
a drainage conduit having a proximal end which is attached to the drainage plate and a distal end which is capable of being placed in the anterior chamber of the eye such that aqueous humor may flow from the anterior chamber of the eye, through the conduit, and onto the drainage plate.
4. The device of claim 3 wherein said drainage conduit has a porous ingrowth surface adjacent to its proximal end.
5. The device of claim 4 including a dissolvable drainage plug located in the conduit, and wherein said plug contains drugs which prevent excessive fibrous capsule formation, such that as the plug dissolves the drugs are released and delivered through the conduit, onto the plate and ultimately to the tissues of the eye which surround the bleb.
6. The device of claim 3 wherein the porous posterior surface of the plate wraps around the side of the plate.
7. The device of claim 3 wherein the porous posterior surface of the plate includes pores which are encapsulated so as to create porous tunnels having entrances and exits that are located on the posterior surface of the drainage plate.
8. A surgically implantable drainage device to facilitate the flow of aqueous humor from an eye comprising
a pliable drainage plate having a smooth, non-porous anterior surface and a porous posterior surface for cellular ingrowth and attachment of the device to the sclera,
a drainage conduit having a proximal end which is attached to the drainage plate and a distal end which is capable of being placed in the anterior chamber of the eye such that aqueous humor may flow from the anterior chamber of the eye, through the conduit, and onto the anterior surface of the plate,
wherein said drainage conduit has a porous ingrowth surface adjacent to its proximal end for cellular ingrowth and attachment of the device to the sclera,
wherein said drainage plate has a ridge rising above its anterior surface in the general area where the drainage conduit is attached to the plate, said ridge having an opening to permit the drainage conduit to pass therethrough, said ridge preventing fibrous capsule tissue from clogging the drainage conduit, and
a dissolvable plug located in the drainage conduit, said plug containing drugs which prevent excess fibrous capsule formation, such that when said surgically implantable drainage device is in use and the plug dissolves, the drugs are released and delivered through the conduit, onto the plate and ultimately to the tissues of the eye which surround the bleb.
US08/839,263 1997-04-17 1997-04-17 Long-term glaucoma drainage implant Expired - Fee Related US5882327A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/839,263 US5882327A (en) 1997-04-17 1997-04-17 Long-term glaucoma drainage implant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/839,263 US5882327A (en) 1997-04-17 1997-04-17 Long-term glaucoma drainage implant

Publications (1)

Publication Number Publication Date
US5882327A true US5882327A (en) 1999-03-16

Family

ID=25279274

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/839,263 Expired - Fee Related US5882327A (en) 1997-04-17 1997-04-17 Long-term glaucoma drainage implant

Country Status (1)

Country Link
US (1) US5882327A (en)

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064511A1 (en) * 1999-04-27 2000-11-02 The Arizona Board Of Regents Acting On Behalf Of The University Of Arizona A glaucoma shunt and a method of making and surgically implanting the same
WO2001078631A2 (en) 2000-04-14 2001-10-25 Glaukos Corporation Apparatus and method for treating glaucoma
US6383218B1 (en) * 1997-02-17 2002-05-07 Corneal Industrie Sclero-ceratectomy implant for descemet's membrane
US6383219B1 (en) * 1997-02-17 2002-05-07 Corneal Industrie Implant for deep sclerectomy
WO2002070045A1 (en) * 2001-01-09 2002-09-12 Brown J David Glaucoma treatment device and method
US6450984B1 (en) 1999-04-26 2002-09-17 Gmp Vision Solutions, Inc. Shunt device and method for treating glaucoma
US20020169130A1 (en) * 2001-05-03 2002-11-14 Hosheng Tu Medical device and methods of use for glaucoma treatment
US20020188308A1 (en) * 2001-04-07 2002-12-12 Hosheng Tu Glaucoma stent and methods thereof for glaucoma treatment
US6533768B1 (en) 2000-04-14 2003-03-18 The Regents Of The University Of California Device for glaucoma treatment and methods thereof
US20030055372A1 (en) * 1999-04-26 2003-03-20 Lynch Mary G. Shunt device and method for treating glaucoma
US20030088260A1 (en) * 2001-11-08 2003-05-08 Smedley Gregory T. Combined treatment for cataract and glaucoma treatment
US20030097151A1 (en) * 2001-10-25 2003-05-22 Smedley Gregory T. Apparatus and mitochondrial treatment for glaucoma
EP1125568A3 (en) * 2000-02-15 2003-09-03 GRIESHABER & CO. AG SCHAFFHAUSEN Method and device to improve as well as to maintain the outflow of the aqueous humor of an eye
US6666841B2 (en) 2001-05-02 2003-12-23 Glaukos Corporation Bifurcatable trabecular shunt for glaucoma treatment
US20040015140A1 (en) * 2002-07-19 2004-01-22 Shields Milton B. Uveoscleral drainage device
US20040024345A1 (en) * 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
EP1310222A3 (en) * 2001-11-08 2004-03-17 Glaukos Corporation Drug-releasing trabecular implant for glaucoma treatment
US20040050392A1 (en) * 2001-08-28 2004-03-18 Hosheng Tu Glaucoma stent for treating glaucoma and methods of use
US20040073156A1 (en) * 2001-01-09 2004-04-15 Brown J. David Glaucoma treatment device and method
US20040092856A1 (en) * 2000-09-01 2004-05-13 Elie Dahan Glaucoma drain
US20040102729A1 (en) * 2002-04-08 2004-05-27 David Haffner Devices and methods for glaucoma treatment
US20040111050A1 (en) * 2000-04-14 2004-06-10 Gregory Smedley Implantable ocular pump to reduce intraocular pressure
US20040127843A1 (en) * 2000-04-14 2004-07-01 Hosheng Tu Glaucoma implant with therapeutic agents
US20040147870A1 (en) * 2002-04-08 2004-07-29 Burns Thomas W. Glaucoma treatment kit
US20040193095A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
US20040225250A1 (en) * 2003-05-05 2004-11-11 Michael Yablonski Internal shunt and method for treating glaucoma
US20040254521A1 (en) * 2003-06-16 2004-12-16 Solx, Inc. Shunt for the treatment of glaucoma
US20040260227A1 (en) * 2002-12-19 2004-12-23 Lisk James R. Article and method for ocular aqueous drainage
US20050049578A1 (en) * 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
US20050107734A1 (en) * 2003-11-14 2005-05-19 Coroneo Minas T. Ocular pressure regulation
US20050119636A1 (en) * 2001-05-02 2005-06-02 David Haffner Implant with intraocular pressure sensor for glaucoma treatment
US20050119737A1 (en) * 2000-01-12 2005-06-02 Bene Eric A. Ocular implant and methods for making and using same
US20050159660A1 (en) * 2002-05-31 2005-07-21 Valentino Montegrande Intraocular pressure sensor
US20050192527A1 (en) * 2001-05-02 2005-09-01 Morteza Gharib Glaucoma implant with extending members
US20050250788A1 (en) * 2004-01-30 2005-11-10 Hosheng Tu Aqueous outflow enhancement with vasodilated aqueous cavity
US20050261624A1 (en) * 2000-10-18 2005-11-24 Wilcox Michael J C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use
US20050266047A1 (en) * 2002-04-08 2005-12-01 Hosheng Tu Injectable glaucoma implants with multiple openings
US20050267398A1 (en) * 2004-05-27 2005-12-01 Dimitri Protopsaltis Glaucoma shunt
US20050271704A1 (en) * 2002-04-08 2005-12-08 Hosheng Tu Injectable glaucoma implants with multiple openings
US20050277864A1 (en) * 2000-04-14 2005-12-15 David Haffner Injectable gel implant for glaucoma treatment
US20060155300A1 (en) * 2002-09-17 2006-07-13 Iscience Surgical, Inc. Apparatus and method for surgical bypass of aqueous humor
US20060189916A1 (en) * 2005-02-21 2006-08-24 Bas Arturo M A Device for draining aqueous humor in cases of glaucoma
US20060235367A1 (en) * 2002-12-27 2006-10-19 Seisuke Takashima Aqueous humor drainage implant for treatment glaucoma
US7186232B1 (en) 2002-03-07 2007-03-06 Glaukoa Corporation Fluid infusion methods for glaucoma treatment
US20070123767A1 (en) * 2002-05-31 2007-05-31 Valentino Montegrande Intraocular pressure sensor and method of use
US20070156079A1 (en) * 2005-09-16 2007-07-05 Bg Implant, Inc. Glaucoma Treatment Devices and Methods
US20070191863A1 (en) * 2006-01-17 2007-08-16 De Juan Eugene Jr Glaucoma Treatment Device
US20070233037A1 (en) * 2006-01-17 2007-10-04 Gifford Hanson S Iii Drug Delivery Treatment Device
US20070293872A1 (en) * 2006-06-20 2007-12-20 Minu, L.L.C. Ocular Drainage Device
US20070293807A1 (en) * 2006-05-01 2007-12-20 Lynch Mary G Dual drainage pathway shunt device and method for treating glaucoma
US20080145403A1 (en) * 2006-12-19 2008-06-19 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US20080172204A1 (en) * 2007-01-15 2008-07-17 Fujitsu Limited Step counter and method of counting steps
US20080277332A1 (en) * 2007-05-11 2008-11-13 Becton, Dickinson And Company Micromachined membrane filter device for a glaucoma implant and method for making the same
US20080306429A1 (en) * 2007-06-07 2008-12-11 Shields Milton B Uveoscleral drainage device
US7488303B1 (en) 2002-09-21 2009-02-10 Glaukos Corporation Ocular implant with anchor and multiple openings
US20090043321A1 (en) * 2004-04-29 2009-02-12 Iscience Interventional Corporation Apparatus And Method For Surgical Enhancement Of Aqueous Humor Drainage
EP2059282A2 (en) * 2006-09-06 2009-05-20 Innfocus, Llc Apparatus, methods and devices for treatment of ocular disorders
US20100057055A1 (en) * 2005-02-23 2010-03-04 Camras Carl B Method and apparatus for reducing intraocular pressure
US20100114006A1 (en) * 2008-11-05 2010-05-06 Advanced Medical Optics, Inc. Glaucoma drainage shunts and methods of use
US20100137981A1 (en) * 2008-06-25 2010-06-03 Silvestrini Thomas A Ocular implant with shape change capabilities
US20100173866A1 (en) * 2004-04-29 2010-07-08 Iscience Interventional Corporation Apparatus and method for ocular treatment
US20100191177A1 (en) * 2009-01-23 2010-07-29 Iscience Interventional Corporation Device for aspirating fluids
US20100249691A1 (en) * 2009-03-26 2010-09-30 Abbott Medical Optics Inc. Glaucoma shunts with flow management and improved surgical performance
US20100274258A1 (en) * 2009-01-28 2010-10-28 Silvestrini Thomas A Ocular implant with stiffness qualities, methods of implantation and system
US20110105990A1 (en) * 2009-11-04 2011-05-05 Silvestrini Thomas A Zonal drug delivery device and method
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US20110238075A1 (en) * 2009-12-23 2011-09-29 Luke Clauson Drug delivery devices and methods
CN101305947B (en) * 2007-05-18 2011-10-12 吴烈 Drainage device special for glaucoma ciliarotomy
US20120302861A1 (en) * 2011-04-27 2012-11-29 Istar Medical Device and method for glaucoma management and treatment
US8425473B2 (en) 2009-01-23 2013-04-23 Iscience Interventional Corporation Subretinal access device
US8506515B2 (en) 2006-11-10 2013-08-13 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US20130317411A1 (en) * 2012-05-23 2013-11-28 Ghansham Das AGARWAL Device for Treatment of Glaucoma
US8672870B2 (en) 2007-07-17 2014-03-18 Transcend Medical, Inc. Ocular implant with hydrogel expansion capabilities
US8771220B2 (en) 2011-12-07 2014-07-08 Alcon Research, Ltd. Glaucoma active pressure regulation shunt
WO2015126332A1 (en) * 2014-02-24 2015-08-27 National University Of Singapore An ocular drainage device and method of manufacturing thereof
US9155656B2 (en) 2012-04-24 2015-10-13 Transcend Medical, Inc. Delivery system for ocular implant
WO2016003294A1 (en) * 2014-07-01 2016-01-07 Mario Eduardo Miranda Velasquez Drainage device for controlling intraocular pressure in glaucoma
US9381112B1 (en) 2011-10-06 2016-07-05 William Eric Sponsell Bleb drainage device, ophthalmological product and methods
US9414962B2 (en) 2012-04-23 2016-08-16 Das Agarwal Ghansham Device for treatment of glaucoma and prevention of sub-scleral fibrosis and blockage
US9480598B2 (en) 2012-09-17 2016-11-01 Novartis Ag Expanding ocular implant devices and methods
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US20180325731A1 (en) * 2017-05-15 2018-11-15 Rainbow Medical Ltd. Eye implant
US10201451B2 (en) 2014-08-29 2019-02-12 Camras Vision Inc. Device and method for reducing intraocular pressure
US10271989B2 (en) 2012-03-26 2019-04-30 Glaukos Corporation System and method for delivering multiple ocular implants
US10342702B2 (en) 2014-08-29 2019-07-09 Camras Vision Inc. Apparatus and method for reducing intraocular pressure
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10524958B2 (en) 2015-09-30 2020-01-07 Alievio, Inc. Method and apparatus for reducing intraocular pressure
JP2020509888A (en) * 2017-03-17 2020-04-02 ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated Integrated aqueous shunt for glaucoma treatment
US10736778B2 (en) 2014-12-31 2020-08-11 Microoptx Inc. Glaucoma treatment devices and methods
US10842916B2 (en) 2015-06-24 2020-11-24 Healionics Corporation Injectable porous device for treatment of dry and wet age-related macular degeneration or diabetic retinopathy
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10980667B2 (en) 2015-09-30 2021-04-20 Microoptx Inc. Eye treatment devices and methods
US11116625B2 (en) 2017-09-28 2021-09-14 Glaukos Corporation Apparatus and method for controlling placement of intraocular implants
CN114129769A (en) * 2021-09-22 2022-03-04 海思盖德(苏州)生物医学科技有限公司 Artificial aqueous humor micro-drainage tube with drug slow-release function and preparation method thereof
CN114632187A (en) * 2021-11-18 2022-06-17 海思盖德(苏州)生物医学科技有限公司 Heparin coating porous micro-stent for aqueous humor drainage of glaucoma
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor
US11617644B2 (en) 2014-10-13 2023-04-04 W. L. Gore & Associates, Inc. Prosthetic valved conduit
US11672701B2 (en) 2018-10-25 2023-06-13 Amo Groningen B.V. Bleb control glaucoma shunts
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
WO2023135547A1 (en) * 2022-01-14 2023-07-20 Liqid Medical Proprietary Limited Shunt and method for treating glaucoma
US11925578B2 (en) 2016-09-01 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457757A (en) * 1981-07-20 1984-07-03 Molteno Anthony C B Device for draining aqueous humour
US4604087A (en) * 1985-02-26 1986-08-05 Joseph Neil H Aqueous humor drainage device
US4634418A (en) * 1984-04-06 1987-01-06 Binder Perry S Hydrogel seton
US4750901A (en) * 1986-03-07 1988-06-14 Molteno Anthony C B Implant for drainage of aqueous humour
US4865601A (en) * 1987-07-07 1989-09-12 Caldwell Delmar R Intraocular prostheses
US4932968A (en) * 1987-07-07 1990-06-12 Caldwell Delmar R Intraocular prostheses
US4936825A (en) * 1988-04-11 1990-06-26 Ungerleider Bruce A Method for reducing intraocular pressure caused by glaucoma
US4946436A (en) * 1989-11-17 1990-08-07 Smith Stewart G Pressure-relieving device and process for implanting
US4955909A (en) * 1989-01-31 1990-09-11 Bioplasty, Inc. Textured silicone implant prosthesis
US5178604A (en) * 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US5192315A (en) * 1992-03-24 1993-03-09 Jacob Labarre Jean T Total ocular replacement apparatus with muscle attachment sites
US5282851A (en) * 1987-07-07 1994-02-01 Jacob Labarre Jean Intraocular prostheses
US5338291A (en) * 1993-02-03 1994-08-16 Pudenz-Schulte Medical Research Corporation Glaucoma shunt and method for draining aqueous humor
US5397300A (en) * 1990-05-31 1995-03-14 Iovision, Inc. Glaucoma implant
US5476445A (en) * 1990-05-31 1995-12-19 Iovision, Inc. Glaucoma implant with a temporary flow restricting seal

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457757A (en) * 1981-07-20 1984-07-03 Molteno Anthony C B Device for draining aqueous humour
US4634418A (en) * 1984-04-06 1987-01-06 Binder Perry S Hydrogel seton
US4604087A (en) * 1985-02-26 1986-08-05 Joseph Neil H Aqueous humor drainage device
US4750901A (en) * 1986-03-07 1988-06-14 Molteno Anthony C B Implant for drainage of aqueous humour
US5282851A (en) * 1987-07-07 1994-02-01 Jacob Labarre Jean Intraocular prostheses
US4865601A (en) * 1987-07-07 1989-09-12 Caldwell Delmar R Intraocular prostheses
US4932968A (en) * 1987-07-07 1990-06-12 Caldwell Delmar R Intraocular prostheses
US4936825A (en) * 1988-04-11 1990-06-26 Ungerleider Bruce A Method for reducing intraocular pressure caused by glaucoma
US5372577A (en) * 1988-04-11 1994-12-13 Ungerleider; Bruce A. Apparatus for reducing intraocular pressure
US4955909A (en) * 1989-01-31 1990-09-11 Bioplasty, Inc. Textured silicone implant prosthesis
US4946436A (en) * 1989-11-17 1990-08-07 Smith Stewart G Pressure-relieving device and process for implanting
US5178604A (en) * 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US5397300A (en) * 1990-05-31 1995-03-14 Iovision, Inc. Glaucoma implant
US5476445A (en) * 1990-05-31 1995-12-19 Iovision, Inc. Glaucoma implant with a temporary flow restricting seal
US5192315A (en) * 1992-03-24 1993-03-09 Jacob Labarre Jean T Total ocular replacement apparatus with muscle attachment sites
US5338291A (en) * 1993-02-03 1994-08-16 Pudenz-Schulte Medical Research Corporation Glaucoma shunt and method for draining aqueous humor

Cited By (299)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383218B1 (en) * 1997-02-17 2002-05-07 Corneal Industrie Sclero-ceratectomy implant for descemet's membrane
US6383219B1 (en) * 1997-02-17 2002-05-07 Corneal Industrie Implant for deep sclerectomy
US20050090807A1 (en) * 1999-04-26 2005-04-28 Gmp Vision Solutions, Inc. Shunt device and method for treating glaucoma
US10568762B2 (en) 1999-04-26 2020-02-25 Glaukos Corporation Stent for treating ocular disorders
US6783544B2 (en) 1999-04-26 2004-08-31 Gmp Vision Solutions, Inc. Stent device and method for treating glaucoma
US6626858B2 (en) 1999-04-26 2003-09-30 Gmp Vision Solutions, Inc. Shunt device and method for treating glaucoma
US6464724B1 (en) 1999-04-26 2002-10-15 Gmp Vision Solutions, Inc. Stent device and method for treating glaucoma
US10492950B2 (en) 1999-04-26 2019-12-03 Glaukos Corporation Shunt device and method for treating ocular disorders
US7850637B2 (en) 1999-04-26 2010-12-14 Glaukos Corporation Shunt device and method for treating glaucoma
US6524275B1 (en) 1999-04-26 2003-02-25 Gmp Vision Solutions, Inc. Inflatable device and method for treating glaucoma
US6827700B2 (en) 1999-04-26 2004-12-07 Gmp Vision Solutions, Inc. Shunt device and method for treating glaucoma
US20030055372A1 (en) * 1999-04-26 2003-03-20 Lynch Mary G. Shunt device and method for treating glaucoma
US20050119601A9 (en) * 1999-04-26 2005-06-02 Lynch Mary G. Shunt device and method for treating glaucoma
US20050090806A1 (en) * 1999-04-26 2005-04-28 Gmp Vision Solutions Inc. Shunt device and method for treating glaucoma
US6827699B2 (en) 1999-04-26 2004-12-07 Gmp Vision Solutions, Inc. Shunt device and method for treating glaucoma
US20100004580A1 (en) * 1999-04-26 2010-01-07 Glaukos Corporation Shunt device and method for treating ocular disorders
US6450984B1 (en) 1999-04-26 2002-09-17 Gmp Vision Solutions, Inc. Shunt device and method for treating glaucoma
US20110196281A1 (en) * 1999-04-26 2011-08-11 Glaukos Corporation Shunt device and method for treating ocular disorders
US8388568B2 (en) 1999-04-26 2013-03-05 Glaukos Corporation Shunt device and method for treating ocular disorders
US8771217B2 (en) 1999-04-26 2014-07-08 Glaukos Corporation Shunt device and method for treating ocular disorders
US20030236484A1 (en) * 1999-04-26 2003-12-25 Gmp Vision Solutions, Inc. Inflatable device and method for treating glaucoma
US9492320B2 (en) 1999-04-26 2016-11-15 Glaukos Corporation Shunt device and method for treating ocular disorders
US8152752B2 (en) 1999-04-26 2012-04-10 Glaukos Corporation Shunt device and method for treating glaucoma
US9827143B2 (en) 1999-04-26 2017-11-28 Glaukos Corporation Shunt device and method for treating ocular disorders
US6699210B2 (en) * 1999-04-27 2004-03-02 The Arizona Board Of Regents Glaucoma shunt and a method of making and surgically implanting the same
WO2000064511A1 (en) * 1999-04-27 2000-11-02 The Arizona Board Of Regents Acting On Behalf Of The University Of Arizona A glaucoma shunt and a method of making and surgically implanting the same
US20050119737A1 (en) * 2000-01-12 2005-06-02 Bene Eric A. Ocular implant and methods for making and using same
EP1125568A3 (en) * 2000-02-15 2003-09-03 GRIESHABER & CO. AG SCHAFFHAUSEN Method and device to improve as well as to maintain the outflow of the aqueous humor of an eye
US20030187385A1 (en) * 2000-04-14 2003-10-02 Bergheim Olav B. Implant with anchor
US7867205B2 (en) 2000-04-14 2011-01-11 Glaukos Corporation Method of delivering an implant for treating an ocular disorder
US20040111050A1 (en) * 2000-04-14 2004-06-10 Gregory Smedley Implantable ocular pump to reduce intraocular pressure
US20040127843A1 (en) * 2000-04-14 2004-07-01 Hosheng Tu Glaucoma implant with therapeutic agents
US9993368B2 (en) 2000-04-14 2018-06-12 Glaukos Corporation System and method for treating an ocular disorder
US6780164B2 (en) 2000-04-14 2004-08-24 Glaukos Corporation L-shaped implant with bi-directional flow
US6736791B1 (en) 2000-04-14 2004-05-18 Glaukos Corporation Glaucoma treatment device
US8273050B2 (en) 2000-04-14 2012-09-25 Glaukos Corporation Ocular implant with anchor and therapeutic agent
US20040210185A1 (en) * 2000-04-14 2004-10-21 Hosheng Tu Glaucoma implant kit
US20180161205A1 (en) * 2000-04-14 2018-06-14 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US20070282245A1 (en) * 2000-04-14 2007-12-06 Glaukos Corporation Glaucoma implant with valve
US8348877B2 (en) 2000-04-14 2013-01-08 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US20040249333A1 (en) * 2000-04-14 2004-12-09 Bergheim Olav B. Glaucoma implant with bi-directional flow
US9789001B2 (en) * 2000-04-14 2017-10-17 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US20040254519A1 (en) * 2000-04-14 2004-12-16 Hosheng Tu Glaucoma treatment device
US6638239B1 (en) 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US20050049578A1 (en) * 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
US20080234624A2 (en) * 2000-04-14 2008-09-25 Glaukos Corporation Ocular implant with anchor and therapeutic agent
US8801648B2 (en) 2000-04-14 2014-08-12 Glaukos Corporation Ocular implant with anchor and methods thereof
US8808219B2 (en) 2000-04-14 2014-08-19 Glaukos Corporation Implant delivery device and methods thereof for treatment of ocular disorders
US10485702B2 (en) 2000-04-14 2019-11-26 Glaukos Corporation System and method for treating an ocular disorder
US8333742B2 (en) 2000-04-14 2012-12-18 Glaukos Corporation Method of delivering an implant for treating an ocular disorder
US8814820B2 (en) 2000-04-14 2014-08-26 Glaukos Corporation Ocular implant with therapeutic agent and methods thereof
US6533768B1 (en) 2000-04-14 2003-03-18 The Regents Of The University Of California Device for glaucoma treatment and methods thereof
EP2260803A2 (en) 2000-04-14 2010-12-15 Glaukos Corporation Ocular implant system for treating glaucoma
US20160175151A1 (en) * 2000-04-14 2016-06-23 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US20050209549A1 (en) * 2000-04-14 2005-09-22 Bergheim Olav B Glaucoma implant with multiple openings
US20050209550A1 (en) * 2000-04-14 2005-09-22 Bergheim Olav B Method of treating glaucoma using an implant having a uniform diameter between the anterior chamber and Schlemm's canal
US6955656B2 (en) 2000-04-14 2005-10-18 Glaukos Corporation Apparatus and method for treating glaucoma
US9066782B2 (en) 2000-04-14 2015-06-30 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
EP2985012A1 (en) 2000-04-14 2016-02-17 Glaukos Corporation Implant for treating ocular disorders
US20100234790A1 (en) * 2000-04-14 2010-09-16 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20100056979A1 (en) * 2000-04-14 2010-03-04 Glaukos Corporation Implantable ocular pump to reduce intraocular pressure
US20050277864A1 (en) * 2000-04-14 2005-12-15 David Haffner Injectable gel implant for glaucoma treatment
US20100010414A1 (en) * 2000-04-14 2010-01-14 Glaukos Corporation Method of delivering an implant for treating an ocular disorder
WO2001078631A2 (en) 2000-04-14 2001-10-25 Glaukos Corporation Apparatus and method for treating glaucoma
EP2078516A2 (en) 2000-04-14 2009-07-15 Glaukos Corporation Implant for treating ocular disorders
US20090137983A1 (en) * 2000-04-14 2009-05-28 Glaukos Corporation Implant delivery device and methods thereof for treatment of ocular disorders
US7118547B2 (en) * 2000-09-01 2006-10-10 Ioltechnologie-Production Glaucoma drain
US20040092856A1 (en) * 2000-09-01 2004-05-13 Elie Dahan Glaucoma drain
US9999543B2 (en) 2000-10-18 2018-06-19 Aq Biomed, Llc C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use
US8926546B2 (en) 2000-10-18 2015-01-06 Aqueous Bomedical, Inc. C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use
US7806847B2 (en) 2000-10-18 2010-10-05 Aqueous Biomedical, Inc. C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use
US20050261624A1 (en) * 2000-10-18 2005-11-24 Wilcox Michael J C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use
US20110098627A1 (en) * 2000-10-18 2011-04-28 Aqueous Biomedical, Inc. C-Shaped Cross Section Tubular Ophthalmic Implant for Reduction of Intraocular Pressure in Glaucomatous Eyes and Method of Use
US8425450B2 (en) 2000-10-18 2013-04-23 Aqueous Biomedical, Inc. C-shaped cross section tubular ophthalmic implant for reduction of intraocular pressure in glaucomatous eyes and method of use
US6881198B2 (en) 2001-01-09 2005-04-19 J. David Brown Glaucoma treatment device and method
US20060276739A1 (en) * 2001-01-09 2006-12-07 Brown J D Glaucoma treatment device and method
US20100168644A1 (en) * 2001-01-09 2010-07-01 Brown J David Glaucoma Treatment Device and Method
US20040073156A1 (en) * 2001-01-09 2004-04-15 Brown J. David Glaucoma treatment device and method
WO2002070045A1 (en) * 2001-01-09 2002-09-12 Brown J David Glaucoma treatment device and method
US20060079828A1 (en) * 2001-01-09 2006-04-13 Brown J D Glaucoma treatment device and method
US6595945B2 (en) * 2001-01-09 2003-07-22 J. David Brown Glaucoma treatment device and method
US8118768B2 (en) 2001-04-07 2012-02-21 Dose Medical Corporation Drug eluting ocular implant with anchor and methods thereof
US20090036819A1 (en) * 2001-04-07 2009-02-05 Glaukos Corporation Drug eluting ocular implant with anchor and methods thereof
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US7857782B2 (en) 2001-04-07 2010-12-28 Glaukos Corporation Ocular implant delivery system and method thereof
US8062244B2 (en) 2001-04-07 2011-11-22 Glaukos Corporation Self-trephining implant and methods thereof for treatment of ocular disorders
US8075511B2 (en) 2001-04-07 2011-12-13 Glaukos Corporation System for treating ocular disorders and methods thereof
US7135009B2 (en) 2001-04-07 2006-11-14 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9155654B2 (en) 2001-04-07 2015-10-13 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US10828473B2 (en) 2001-04-07 2020-11-10 Glaukos Corporation Ocular implant delivery system and methods thereof
US20020188308A1 (en) * 2001-04-07 2002-12-12 Hosheng Tu Glaucoma stent and methods thereof for glaucoma treatment
US9987472B2 (en) 2001-04-07 2018-06-05 Glaukos Corporation Ocular implant delivery systems
US20070112292A1 (en) * 2001-04-07 2007-05-17 Hosheng Tu Glaucoma stent and methods thereof for glaucoma treatment
US9572963B2 (en) 2001-04-07 2017-02-21 Glaukos Corporation Ocular disorder treatment methods and systems
US20090138022A1 (en) * 2001-04-07 2009-05-28 Glaukos Corporation Ocular implant delivery system and method thereof
US8579846B2 (en) 2001-04-07 2013-11-12 Glaukos Corporation Ocular implant systems
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
US20050192527A1 (en) * 2001-05-02 2005-09-01 Morteza Gharib Glaucoma implant with extending members
US20050119636A1 (en) * 2001-05-02 2005-06-02 David Haffner Implant with intraocular pressure sensor for glaucoma treatment
US6666841B2 (en) 2001-05-02 2003-12-23 Glaukos Corporation Bifurcatable trabecular shunt for glaucoma treatment
US20090076436A2 (en) * 2001-05-02 2009-03-19 Glaukos Corporation Ocular implants with deployable structure
US8142364B2 (en) 2001-05-02 2012-03-27 Dose Medical Corporation Method of monitoring intraocular pressure and treating an ocular disorder
US20100106073A1 (en) * 2001-05-02 2010-04-29 Glaukos Corporation Method of monitoring intraocular pressure and treating an ocular disorder
US6981958B1 (en) 2001-05-02 2006-01-03 Glaukos Corporation Implant with pressure sensor for glaucoma treatment
US20080015488A1 (en) * 2001-05-03 2008-01-17 Glaukos Corporation Glaucoma implant with double anchor mechanism
US20020169130A1 (en) * 2001-05-03 2002-11-14 Hosheng Tu Medical device and methods of use for glaucoma treatment
US7273475B2 (en) 2001-05-03 2007-09-25 Glaukos Corporation Medical device and methods of use for glaucoma treatment
US8337445B2 (en) 2001-05-03 2012-12-25 Glaukos Corporation Ocular implant with double anchor mechanism
US7094225B2 (en) 2001-05-03 2006-08-22 Glaukos Corporation Medical device and methods of use of glaucoma treatment
US20070010827A1 (en) * 2001-08-28 2007-01-11 Hosheng Tu Glaucoma stent system
US20040050392A1 (en) * 2001-08-28 2004-03-18 Hosheng Tu Glaucoma stent for treating glaucoma and methods of use
US7879079B2 (en) 2001-08-28 2011-02-01 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US7331984B2 (en) 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US9561131B2 (en) 2001-08-28 2017-02-07 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US20060241749A1 (en) * 2001-08-28 2006-10-26 Hosheng Tu Glaucoma stent system
US10285856B2 (en) 2001-08-28 2019-05-14 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US20030097151A1 (en) * 2001-10-25 2003-05-22 Smedley Gregory T. Apparatus and mitochondrial treatment for glaucoma
US7163543B2 (en) 2001-11-08 2007-01-16 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
EP1310222A3 (en) * 2001-11-08 2004-03-17 Glaukos Corporation Drug-releasing trabecular implant for glaucoma treatment
US20030088260A1 (en) * 2001-11-08 2003-05-08 Smedley Gregory T. Combined treatment for cataract and glaucoma treatment
US9220632B2 (en) 2002-03-07 2015-12-29 Glaukos Corporation Fluid infusion methods for ocular disorder treatment
US8617094B2 (en) 2002-03-07 2013-12-31 Glaukos Corporation Fluid infusion methods for glaucoma treatment
US7186232B1 (en) 2002-03-07 2007-03-06 Glaukoa Corporation Fluid infusion methods for glaucoma treatment
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US8882781B2 (en) 2002-03-15 2014-11-11 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US20040147870A1 (en) * 2002-04-08 2004-07-29 Burns Thomas W. Glaucoma treatment kit
US9597230B2 (en) 2002-04-08 2017-03-21 Glaukos Corporation Devices and methods for glaucoma treatment
US20040102729A1 (en) * 2002-04-08 2004-05-27 David Haffner Devices and methods for glaucoma treatment
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US7879001B2 (en) 2002-04-08 2011-02-01 Glaukos Corporation Devices and methods for treatment of ocular disorders
US20050271704A1 (en) * 2002-04-08 2005-12-08 Hosheng Tu Injectable glaucoma implants with multiple openings
US20050266047A1 (en) * 2002-04-08 2005-12-01 Hosheng Tu Injectable glaucoma implants with multiple openings
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US10485701B2 (en) 2002-04-08 2019-11-26 Glaukos Corporation Devices and methods for glaucoma treatment
US20040024345A1 (en) * 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
US20070123767A1 (en) * 2002-05-31 2007-05-31 Valentino Montegrande Intraocular pressure sensor and method of use
US20050159660A1 (en) * 2002-05-31 2005-07-21 Valentino Montegrande Intraocular pressure sensor
US7041077B2 (en) 2002-07-19 2006-05-09 Yale University Uveoscleral drainage device
US20040015140A1 (en) * 2002-07-19 2004-01-22 Shields Milton B. Uveoscleral drainage device
US7699882B2 (en) 2002-09-17 2010-04-20 Iscience Interventional Corporation Apparatus and method for surgical bypass of aqueous humor
US20060155300A1 (en) * 2002-09-17 2006-07-13 Iscience Surgical, Inc. Apparatus and method for surgical bypass of aqueous humor
US8007459B2 (en) 2002-09-21 2011-08-30 Glaukos Corporation Ocular implant with anchoring mechanism and multiple outlets
US7488303B1 (en) 2002-09-21 2009-02-10 Glaukos Corporation Ocular implant with anchor and multiple openings
US7160264B2 (en) 2002-12-19 2007-01-09 Medtronic-Xomed, Inc. Article and method for ocular aqueous drainage
US20040260227A1 (en) * 2002-12-19 2004-12-23 Lisk James R. Article and method for ocular aqueous drainage
US20060235367A1 (en) * 2002-12-27 2006-10-19 Seisuke Takashima Aqueous humor drainage implant for treatment glaucoma
US20040193095A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
US9844462B2 (en) 2003-05-05 2017-12-19 Novartis Ag Internal shunt and method for treating glaucoma
US8444588B2 (en) 2003-05-05 2013-05-21 Transcend Medical, Inc. Internal shunt and method for treating glaucoma
US8945038B2 (en) 2003-05-05 2015-02-03 Transcend Medical, Inc. Internal shunt and method for treating glaucoma
US20040225250A1 (en) * 2003-05-05 2004-11-11 Michael Yablonski Internal shunt and method for treating glaucoma
US20070149915A1 (en) * 2003-05-05 2007-06-28 Judith Yablonski Internal shunt and method for treating glaucoma
US7207965B2 (en) 2003-06-16 2007-04-24 Solx, Inc. Shunt for the treatment of glaucoma
US20040254521A1 (en) * 2003-06-16 2004-12-16 Solx, Inc. Shunt for the treatment of glaucoma
US10226380B2 (en) 2003-11-14 2019-03-12 Novartis Ag Ocular pressure regulation
US8771218B2 (en) 2003-11-14 2014-07-08 Transcend Medical, Inc. Ocular pressure regulation
US8128588B2 (en) 2003-11-14 2012-03-06 Transcend Medical, Inc. Ocular pressure regulation
US20070106235A1 (en) * 2003-11-14 2007-05-10 Coroneo Minas T Ocular Pressure Regulation
US7815592B2 (en) 2003-11-14 2010-10-19 Transcend Medical, Inc. Ocular pressure regulation
US7291125B2 (en) 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
US8808220B2 (en) 2003-11-14 2014-08-19 Transcend Medical, Inc. Ocular pressure regulation
US8728021B2 (en) 2003-11-14 2014-05-20 Transcend Medical, Inc. Ocular pressure regulation
US7850638B2 (en) 2003-11-14 2010-12-14 Transcend Medical, Inc. Ocular pressure regulation
US9351873B2 (en) 2003-11-14 2016-05-31 Transcend Medical, Inc. Ocular pressure regulation
US20110028884A1 (en) * 2003-11-14 2011-02-03 Minas Theodore Coroneo Ocular pressure regulation
US20050107734A1 (en) * 2003-11-14 2005-05-19 Coroneo Minas T. Ocular pressure regulation
US20110087151A1 (en) * 2003-11-14 2011-04-14 Minas Theodore Coroneo Ocular pressure regulation
US20110087149A1 (en) * 2003-11-14 2011-04-14 Minas Theodore Coroneo Ocular pressure regulation
US8486000B2 (en) 2003-11-14 2013-07-16 Transcend Medical, Inc. Ocular pressure regulation
US8758289B2 (en) 2003-11-14 2014-06-24 Transcend Medical, Inc. Ocular pressure regulation
US20050250788A1 (en) * 2004-01-30 2005-11-10 Hosheng Tu Aqueous outflow enhancement with vasodilated aqueous cavity
US20090043321A1 (en) * 2004-04-29 2009-02-12 Iscience Interventional Corporation Apparatus And Method For Surgical Enhancement Of Aqueous Humor Drainage
US20100173866A1 (en) * 2004-04-29 2010-07-08 Iscience Interventional Corporation Apparatus and method for ocular treatment
US20050267398A1 (en) * 2004-05-27 2005-12-01 Dimitri Protopsaltis Glaucoma shunt
US20060189916A1 (en) * 2005-02-21 2006-08-24 Bas Arturo M A Device for draining aqueous humor in cases of glaucoma
US7811268B2 (en) * 2005-02-21 2010-10-12 Artom S.A. Device for draining aqueous humor in cases of glaucoma
US20100057055A1 (en) * 2005-02-23 2010-03-04 Camras Carl B Method and apparatus for reducing intraocular pressure
US9186274B2 (en) * 2005-02-23 2015-11-17 Camras Vision Inc. Method and apparatus for reducing intraocular pressure
US20070156079A1 (en) * 2005-09-16 2007-07-05 Bg Implant, Inc. Glaucoma Treatment Devices and Methods
US8734378B2 (en) 2006-01-17 2014-05-27 Transcend Medical, Inc. Glaucoma treatment device
US11786402B2 (en) 2006-01-17 2023-10-17 Alcon Inc. Glaucoma treatment device
US9084662B2 (en) 2006-01-17 2015-07-21 Transcend Medical, Inc. Drug delivery treatment device
US9421130B2 (en) 2006-01-17 2016-08-23 Novartis Ag. Glaucoma treatment device
US20110028883A1 (en) * 2006-01-17 2011-02-03 Juan Jr Eugene De Glaucoma treatment device
US10905590B2 (en) 2006-01-17 2021-02-02 Alcon Inc. Glaucoma treatment device
US9668917B2 (en) 2006-01-17 2017-06-06 Novartis Ag Drug delivery treatment device
US20070233037A1 (en) * 2006-01-17 2007-10-04 Gifford Hanson S Iii Drug Delivery Treatment Device
US20070191863A1 (en) * 2006-01-17 2007-08-16 De Juan Eugene Jr Glaucoma Treatment Device
US8801649B2 (en) 2006-01-17 2014-08-12 Transcend Medical, Inc. Glaucoma treatment device
US8721656B2 (en) 2006-01-17 2014-05-13 Transcend Medical, Inc. Glaucoma treatment device
US9398977B2 (en) 2006-01-17 2016-07-26 Transcend Medical, Inc. Glaucoma treatment device
US9789000B2 (en) 2006-01-17 2017-10-17 Novartis Ag Glaucoma treatment device
US8814819B2 (en) 2006-01-17 2014-08-26 Transcend Medical, Inc. Glaucoma treatment device
US20070293807A1 (en) * 2006-05-01 2007-12-20 Lynch Mary G Dual drainage pathway shunt device and method for treating glaucoma
US20070293872A1 (en) * 2006-06-20 2007-12-20 Minu, L.L.C. Ocular Drainage Device
EP2059282A2 (en) * 2006-09-06 2009-05-20 Innfocus, Llc Apparatus, methods and devices for treatment of ocular disorders
US20100241046A1 (en) * 2006-09-06 2010-09-23 Innfocus, Llc Apparatus, methods and devices for treatment of ocular disorders
EP2059282A4 (en) * 2006-09-06 2014-04-09 Innfocus Inc Apparatus, methods and devices for treatment of ocular disorders
US9962290B2 (en) 2006-11-10 2018-05-08 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US8506515B2 (en) 2006-11-10 2013-08-13 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US10828195B2 (en) 2006-11-10 2020-11-10 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
JP2010513555A (en) * 2006-12-19 2010-04-30 アラーガン、インコーポレイテッド Method for producing cyclic lipid implants for intraocular use
US10441543B2 (en) 2006-12-19 2019-10-15 Allergan, Inc. Processes for making cyclic lipid implants for intraocular use
US20080145403A1 (en) * 2006-12-19 2008-06-19 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US9149428B2 (en) 2006-12-19 2015-10-06 Allergan, Inc. Processes for making cyclic lipid implants for intraocular use
US20080172204A1 (en) * 2007-01-15 2008-07-17 Fujitsu Limited Step counter and method of counting steps
US20080277332A1 (en) * 2007-05-11 2008-11-13 Becton, Dickinson And Company Micromachined membrane filter device for a glaucoma implant and method for making the same
CN101305947B (en) * 2007-05-18 2011-10-12 吴烈 Drainage device special for glaucoma ciliarotomy
US20080306429A1 (en) * 2007-06-07 2008-12-11 Shields Milton B Uveoscleral drainage device
US8672870B2 (en) 2007-07-17 2014-03-18 Transcend Medical, Inc. Ocular implant with hydrogel expansion capabilities
US9585789B2 (en) 2007-07-17 2017-03-07 Novartis Ag Ocular implant with hydrogel expansion capabilities
US8617139B2 (en) 2008-06-25 2013-12-31 Transcend Medical, Inc. Ocular implant with shape change capabilities
US10016301B2 (en) 2008-06-25 2018-07-10 Novartis Ag Ocular implant with shape change capabilities
US20100137981A1 (en) * 2008-06-25 2010-06-03 Silvestrini Thomas A Ocular implant with shape change capabilities
US20100114006A1 (en) * 2008-11-05 2010-05-06 Advanced Medical Optics, Inc. Glaucoma drainage shunts and methods of use
US8353856B2 (en) * 2008-11-05 2013-01-15 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US8920357B2 (en) 2008-11-05 2014-12-30 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US9468558B2 (en) 2008-11-05 2016-10-18 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US10492948B2 (en) 2008-11-05 2019-12-03 Johnson & Johnson Surgical Vision, Inc. Glaucoma drainage shunts and methods of use
US20170020731A1 (en) * 2008-11-05 2017-01-26 Abbott Medical Optics Inc. Glaucoma drainage shunts and methods of use
US8425473B2 (en) 2009-01-23 2013-04-23 Iscience Interventional Corporation Subretinal access device
US20100191177A1 (en) * 2009-01-23 2010-07-29 Iscience Interventional Corporation Device for aspirating fluids
US8262726B2 (en) 2009-01-28 2012-09-11 Transcend Medical, Inc. Ocular implant with stiffness qualities, methods of implantation and system
US8377122B2 (en) 2009-01-28 2013-02-19 Transcend Medical, Inc. Ocular implant with stiffness qualities, methods of implantation and system
US20110028983A1 (en) * 2009-01-28 2011-02-03 Silvestrini Thomas A Ocular implant with stiffness qualities, methods of implantation and system
US11839571B2 (en) 2009-01-28 2023-12-12 Alcon Inc. Ocular implant with stiffness qualities, methods of implantation and system
US20100274258A1 (en) * 2009-01-28 2010-10-28 Silvestrini Thomas A Ocular implant with stiffness qualities, methods of implantation and system
US10531983B2 (en) 2009-01-28 2020-01-14 Novartis Ag Ocular implant with stiffness qualities, methods of implantation and system
US8172899B2 (en) 2009-01-28 2012-05-08 Transcend Medical, Inc. Ocular implant with stiffness qualities, methods of implantation and system
US8574294B2 (en) 2009-01-28 2013-11-05 Transcend Medical, Inc. Ocular implant with stiffness qualities, methods of implantation and system
US8167939B2 (en) 2009-01-28 2012-05-01 Transcend Medical, Inc. Ocular implant with stiffness qualities, methods of implantation and system
US11344448B2 (en) 2009-01-28 2022-05-31 Alcon Inc. Ocular implant with stiffness qualities, methods of implantation and system
US9763828B2 (en) 2009-01-28 2017-09-19 Novartis Ag Ocular implant with stiffness qualities, methods of implantation and system
US20110087148A1 (en) * 2009-01-28 2011-04-14 Silvestrini Thomas A Ocular implant with stiffness qualities, methods of implantation and system
US20100249691A1 (en) * 2009-03-26 2010-09-30 Abbott Medical Optics Inc. Glaucoma shunts with flow management and improved surgical performance
WO2010111528A3 (en) * 2009-03-26 2011-03-24 Abbott Medical Optics Inc. Glaucoma shunts with flow management and improved surgical performance
US8702639B2 (en) 2009-03-26 2014-04-22 Abbott Medical Optics Inc. Glaucoma shunts with flow management and improved surgical performance
EP2789318A3 (en) * 2009-03-26 2015-02-18 Abbott Medical Optics Inc. Glaucoma shunts with flow management and improved surgical performance
US20110105990A1 (en) * 2009-11-04 2011-05-05 Silvestrini Thomas A Zonal drug delivery device and method
US20110238075A1 (en) * 2009-12-23 2011-09-29 Luke Clauson Drug delivery devices and methods
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US9549846B2 (en) 2009-12-23 2017-01-24 Novartis Ag Drug delivery devices and methods
US9089392B2 (en) 2009-12-23 2015-07-28 Transcend Medical, Inc. Drug delivery devices and methods
US20120302861A1 (en) * 2011-04-27 2012-11-29 Istar Medical Device and method for glaucoma management and treatment
CN103517667A (en) * 2011-04-27 2014-01-15 Istar医疗公司 Improvements in or relating to glaucoma management and treatment
CN103517667B (en) * 2011-04-27 2016-11-09 Istar医疗公司 The improvement improving or relating to glaucoma management and treatment in glaucoma management and treatment
US8926510B2 (en) * 2011-04-27 2015-01-06 Istar Medical Sa Device and method for glaucoma management and treatment
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor
US11065154B1 (en) 2011-10-06 2021-07-20 William Eric Sponsel Bleb drainage device, ophthalmic product and methods
US9381112B1 (en) 2011-10-06 2016-07-05 William Eric Sponsell Bleb drainage device, ophthalmological product and methods
US8771220B2 (en) 2011-12-07 2014-07-08 Alcon Research, Ltd. Glaucoma active pressure regulation shunt
US11197780B2 (en) 2012-03-26 2021-12-14 Glaukos Corporation System and method for delivering multiple ocular implants
US10271989B2 (en) 2012-03-26 2019-04-30 Glaukos Corporation System and method for delivering multiple ocular implants
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US9414962B2 (en) 2012-04-23 2016-08-16 Das Agarwal Ghansham Device for treatment of glaucoma and prevention of sub-scleral fibrosis and blockage
US10912676B2 (en) 2012-04-24 2021-02-09 Alcon Inc. Delivery system for ocular implant
US9907697B2 (en) 2012-04-24 2018-03-06 Novartis Ag Delivery system for ocular implant
US9155656B2 (en) 2012-04-24 2015-10-13 Transcend Medical, Inc. Delivery system for ocular implant
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
US20130317411A1 (en) * 2012-05-23 2013-11-28 Ghansham Das AGARWAL Device for Treatment of Glaucoma
US9480598B2 (en) 2012-09-17 2016-11-01 Novartis Ag Expanding ocular implant devices and methods
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
US10849558B2 (en) 2013-03-13 2020-12-01 Glaukos Corporation Intraocular physiological sensor
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US11559430B2 (en) 2013-03-15 2023-01-24 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10188551B2 (en) 2013-03-15 2019-01-29 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US9808374B2 (en) 2014-02-24 2017-11-07 National University Of Singapore Ocular drainage device and method of manufacturing thereof
WO2015126332A1 (en) * 2014-02-24 2015-08-27 National University Of Singapore An ocular drainage device and method of manufacturing thereof
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2016003294A1 (en) * 2014-07-01 2016-01-07 Mario Eduardo Miranda Velasquez Drainage device for controlling intraocular pressure in glaucoma
US10201451B2 (en) 2014-08-29 2019-02-12 Camras Vision Inc. Device and method for reducing intraocular pressure
US10342702B2 (en) 2014-08-29 2019-07-09 Camras Vision Inc. Apparatus and method for reducing intraocular pressure
US10369050B2 (en) 2014-08-29 2019-08-06 Camras Vision Inc. Device and method for reducing intraocular pressure
US11617644B2 (en) 2014-10-13 2023-04-04 W. L. Gore & Associates, Inc. Prosthetic valved conduit
US10736778B2 (en) 2014-12-31 2020-08-11 Microoptx Inc. Glaucoma treatment devices and methods
US10842916B2 (en) 2015-06-24 2020-11-24 Healionics Corporation Injectable porous device for treatment of dry and wet age-related macular degeneration or diabetic retinopathy
US10980667B2 (en) 2015-09-30 2021-04-20 Microoptx Inc. Eye treatment devices and methods
US10524958B2 (en) 2015-09-30 2020-01-07 Alievio, Inc. Method and apparatus for reducing intraocular pressure
US11925578B2 (en) 2016-09-01 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11523940B2 (en) 2017-03-17 2022-12-13 W. L. Gore & Associates, Inc. Delivery aids for glaucoma shunts
JP2020509888A (en) * 2017-03-17 2020-04-02 ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated Integrated aqueous shunt for glaucoma treatment
US11351058B2 (en) 2017-03-17 2022-06-07 W. L. Gore & Associates, Inc. Glaucoma treatment systems and methods
CN113616415A (en) * 2017-03-17 2021-11-09 W.L.戈尔及同仁股份有限公司 Integrated aqueous humor shunt for treating glaucoma
US11406533B2 (en) 2017-03-17 2022-08-09 W. L. Gore & Associates, Inc. Integrated aqueous shunt for glaucoma treatment
CN114522019A (en) * 2017-03-17 2022-05-24 W.L.戈尔及同仁股份有限公司 Integrated aqueous humor shunt for glaucoma treatment
US20180325731A1 (en) * 2017-05-15 2018-11-15 Rainbow Medical Ltd. Eye implant
US11116625B2 (en) 2017-09-28 2021-09-14 Glaukos Corporation Apparatus and method for controlling placement of intraocular implants
US11672701B2 (en) 2018-10-25 2023-06-13 Amo Groningen B.V. Bleb control glaucoma shunts
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
CN114129769A (en) * 2021-09-22 2022-03-04 海思盖德(苏州)生物医学科技有限公司 Artificial aqueous humor micro-drainage tube with drug slow-release function and preparation method thereof
CN114129769B (en) * 2021-09-22 2022-08-05 海思盖德(苏州)生物医学科技有限公司 Artificial aqueous humor micro-drainage tube with drug slow-release function and preparation method thereof
CN114632187B (en) * 2021-11-18 2022-10-04 海思盖德(苏州)生物医学科技有限公司 Heparin coating porous micro-stent for aqueous humor drainage of glaucoma
CN114632187A (en) * 2021-11-18 2022-06-17 海思盖德(苏州)生物医学科技有限公司 Heparin coating porous micro-stent for aqueous humor drainage of glaucoma
WO2023135547A1 (en) * 2022-01-14 2023-07-20 Liqid Medical Proprietary Limited Shunt and method for treating glaucoma

Similar Documents

Publication Publication Date Title
US5882327A (en) Long-term glaucoma drainage implant
JP5662436B2 (en) Fiber matrix that maintains space in soft tissue
US10492948B2 (en) Glaucoma drainage shunts and methods of use
JP3088746B2 (en) Glaucoma implant
US5626558A (en) Adjustable flow rate glaucoma shunt and method of using same
JP4011477B2 (en) A device implanted in the eye to act as a conduit for aqueous humor
US5476445A (en) Glaucoma implant with a temporary flow restricting seal
US5338291A (en) Glaucoma shunt and method for draining aqueous humor
US6186974B1 (en) Device for use in the eye
US4902292A (en) Vitreous body prosthesis device
JP4499986B2 (en) Glaucoma drain
US20030229303A1 (en) Expandable glaucoma implant and methods of use
US20030236483A1 (en) Dual drainage ocular shunt for glaucoma
MXPA02009939A (en) Device for glaucoma treatment and methods thereof.
WO1993020783A1 (en) Glaucoma implant
US11116662B2 (en) Glaucoma pump implant working by means of iris movements to reduce intraocular pressure
WO2013059830A1 (en) Biocompatible glaucoma drainage device

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JACOB, JEAN T.;REEL/FRAME:010033/0648

Effective date: 19990602

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20110316